The TOGETHER Project - Kidney RNA-seq Validation

N/ACompletedNCT03874299

Mayo Clinic302 enrolled

Overview

The researchers are trying to develop a way to measure the risk of rejection through the validation of a blood test.

Study Type

OBSERVATIONAL

Enrollment

302

Conditions

Kidney Transplant Rejection

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult (\>/=18 years) renal transplant recipient. * Patients who have given informed consent and are willing to comply with the protocol, including the use of their peripheral blood specimens and data for subsequent research. Exclusion Criteria: -Adult (\<18 years) renal transplant recipient.

Locations (3)

Mayo Clinic

Scottsdale, Arizona, United States

Mayo Clinic

Jacksonville, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

To validate the use of a RNA-seq based peripheral blood assay in renal transplant recipients.

The study will validate the ability of a peripheral blood assay to assess the risk of biopsy proven rejection.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.